Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

J. R. Brahmer, J. W. Lee, A. M. Traynor, M. M. Hidalgo, J. M. Kolesar, J. M. Siegfried, P. P. Guaglianone, J. D. Patel, M. D. Keppen, J. H. Schiller

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science